相似文献
1
Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry.
Br J Cancer. 1989 Dec;60(6):938-41. doi: 10.1038/bjc.1989.394.
2
Epirubicin in breast cancer patients with liver metastases and abnormal liver biochemistry: initial weekly treatment followed by rescheduling and intensification.
Ann Oncol. 1991 Oct;2(9):663-6. doi: 10.1093/oxfordjournals.annonc.a058045.
3
Clinical pharmacokinetics of epirubicin: the importance of liver biochemistry tests.
Br J Cancer. 1992 Oct;66(4):765-9. doi: 10.1038/bjc.1992.353.
4
Epirubicin in patients with liver dysfunction: development and evaluation of a novel dose modification scheme.
Eur J Cancer. 2003 Mar;39(5):580-6. doi: 10.1016/s0959-8049(02)00669-x.
5
Effective palliation of advanced breast cancer with weekly low dose epirubicin.
Eur J Cancer Clin Oncol. 1989 Feb;25(2):357-60. doi: 10.1016/0277-5379(89)90030-8.
6
A population model of epirubicin pharmacokinetics and application to dosage guidelines.
Cancer Chemother Pharmacol. 2003 Jul;52(1):34-40. doi: 10.1007/s00280-003-0608-x. Epub 2003 May 23.
7
Epirubicin in hepatocellular carcinoma: pharmacokinetics and clinical activity.
Cancer Chemother Pharmacol. 1994;34(5):405-10. doi: 10.1007/BF00685565.
8
Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity.
Anticancer Drugs. 2009 Feb;20(2):109-14. doi: 10.1097/CAD.0b013e32831bc09b.
9
Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM).
Br J Cancer. 1995 Nov;72(5):1245-50. doi: 10.1038/bjc.1995.494.
10
Weekly epirubicin and paclitaxel with granulocyte colony-stimulating factor support in previously untreated metastatic breast cancer patients: a phase II study.
Anticancer Drugs. 2007 Jul;18(6):687-92. doi: 10.1097/CAD.0b013e328035f863.
引用本文的文献
1
Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients.
Antibodies (Basel). 2019 Jan 1;8(1):3. doi: 10.3390/antib8010003.
2
The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents.
Nanomedicine (Lond). 2015 Feb;10(3):447-63. doi: 10.2217/nnm.14.179.
3
Dose adaptation of antineoplastic drugs in patients with liver disease.
Drug Saf. 2006;29(6):509-22. doi: 10.2165/00002018-200629060-00004.
4
Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90).
Br J Cancer. 1998 May;77(9):1474-9. doi: 10.1038/bjc.1998.242.
5
Anthracycline doses in patients with liver dysfunction: do UK oncologists follow current recommendations?
Br J Cancer. 1998 Apr;77(7):1145-8. doi: 10.1038/bjc.1998.190.
6
Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer.
Br J Cancer. 1996 Dec;74(12):2008-12. doi: 10.1038/bjc.1996.668.
7
Chemotherapy of advanced breast cancer: outcome and prognostic factors.
Br J Cancer. 1993 Nov;68(5):988-95. doi: 10.1038/bjc.1993.467.
8
Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.
Drugs. 1993 May;45(5):788-856. doi: 10.2165/00003495-199345050-00011.
9
Breast cancer and liver metastases--incidence, diagnosis and outcome.
J R Soc Med. 1992 Aug;85(8):508.
本文引用的文献
1
Reporting results of cancer treatment.
Cancer. 1981 Jan 1;47(1):207-14. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6.
2
Pharmacokinetic studies of 4'-epi-doxorubicin in cancer patients with normal and impaired renal function and with hepatic metastases.
Cancer Treat Rep. 1982 Oct;66(10):1819-24.
3
Adriamycin alone or combined with vincristine in the treatment of advanced breast cancer.
Eur J Cancer Clin Oncol. 1983 Nov;19(11):1553-7. doi: 10.1016/0277-5379(83)90085-8.
4
The systemic chemotherapy of hepatic metastases.
Semin Oncol. 1983 Jun;10(2):148-58.
5
Adriamycin chemotherapy--efficacy, safety, and pharmacologic basis of an intermittent single high-dosage schedule.
Cancer. 1974 Jan;33(1):19-27. doi: 10.1002/1097-0142(197401)33:1<19::aid-cncr2820330107>3.0.co;2-m.
6
Clinical pharmacology of cyclophosphamide.
Cancer Res. 1973 Feb;33(2):226-33.
7
The clinical course of bone metastases from breast cancer.
Br J Cancer. 1987 Jan;55(1):61-6. doi: 10.1038/bjc.1987.13.
8
Subclinical hepatic toxicity during combination chemotherapy for breast cancer.
JAMA. 1986 Dec 5;256(21):2988-90.
9
Phase II study of doxorubicin versus epirubicin in advanced breast cancer.
Cancer Treat Rep. 1986 Feb;70(2):261-6.
10
A comparison of two doses of adriamycin in the primary chemotherapy of disseminated breast carcinoma.
Br J Cancer. 1987 Oct;56(4):471-3. doi: 10.1038/bjc.1987.226.
Zotero 插件